JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes | Scientific Reports
PRISE EN CHARGE DES CANCERS DU SEIN HORMONODÉPENDANTS
Luminal B Breast Cancer - an overview | ScienceDirect Topics
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
The expression of ki-67 by subtypes tumor of breast cancer | Download Scientific Diagram
Scholarly Article or Book Chapter | Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | ID: h989r975x | Carolina Digital Repository
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series - Article (Preprint v1) by Rusen Cosar et al. | Qeios
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png "PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar")
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram
Performance of Ki67 (as a continuous variable) to predict Luminal A or... | Download Scientific Diagram
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
Subtypes of Breast Cancer: Luminal B - StoryMD
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
ROC curve to determine the best Ki-67 cut-point to differentiate... | Download Scientific Diagram
